Health Canada approves Livmarli for progressive familial intrahepatic cholestasis in Canada

financialpost.com

Health Canada has authorized LIVMARLI for treating cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). The authorization includes both oral solution and tablet formulations, offering flexible dosing for patients aged 12 months and older with this rare pediatric liver disease. This approval, supported by the MARCH study, provides a new treatment option for PFIC patients in Canada experiencing severe itching, a common and burdensome symptom.


With a significance score of 2.3, this news ranks in the top 17% of today's 27916 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Health Canada approves Livmarli for progressive familial intrahepatic cholestasis in Canada | News Minimalist